On January 20, 2021, Kaleido Biosciences, Inc. and Katharine Knobil, M.D. reached a mutual agreement that Dr. Knobil will resign from her position as Chief Medical Officer and Head of Research and Development of the Company, effective as of January 29, 2021. Dr. Knobil is leaving the Company in order to pursue other opportunities and her decision to resign was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices. In connection with her departure, the Company and Dr. Knobil entered into a separation agreement and general release dated as of January 25, 2021.